Skip to main content

Value Matters


Wallace R. Weitz, CFA

Co-Chief Investment Officer, Portfolio Manager

Bradley P. Hinton, CFA

Co-Chief Investment Officer, Portfolio Manager


The stock market roared back in the second quarter, recovering a good part of its first quarter losses. Our stock funds each showed strong gains: Value +19.2%, Partners Value +18.3%, Hickory +18.2%, and Partners III Opportunity +11.4%. After the steep decline in the first quarter, our year-to-date results, like those of the broader market indices, are still modestly in the red, but the second quarter rebound was a welcome reversal.

The bond market stabilized in the second quarter, thanks to massive intervention by the Federal Reserve, and our bond funds bounced back nicely. They also benefited from the bargains bought during the liquidity panic in March. Short Duration rose +3.8% for the quarter, Core Plus +8.5%, and Nebraska Tax-Free +1.8%. Each fund showed positive year-to-date returns.

EQUITY YTD 1 YR 5 YR 10 YR Since Fund Inception* Inception Date Net Expense Gross Expense
Hickory Fund (WEHIX) -14.50%  -7.32% -1.92% 8.07% 8.79% 4/1/1993* 1.09% 1.27%
Russell Midcap® -9.13%  -2.24% 6.76% 12.35% 10.32%      
Partners III Opportunity Fund - Investor (WPOIX) -6.82%  0.58% 3.65% 9.18% 11.79% 8/1/2011 2.13% 2.13%
Partners III Opportunity Fund - Institutional (WPOPX) -6.59%  1.15% 4.18% 9.58% 11.91% 6/1/1983* 1.56% 1.56%
S&P 500® -3.08% 7.51% 10.73% 13.99% 10.90%      
Russell 3000® -3.48% 6.53% 10.03% 13.72% 10.66%      
Partners Value Fund - Investor (WPVLX) -12.89% -5.06% 2.11% 8.48% 11.06% 7/31/2014 1.09% 1.27%
Partners Value Fund - Institutional (WPVIX) -12.78% -4.82% 2.37% 8.64% 11.10% 6/1/1983* 0.89% 1.07%
S&P 500® -3.08% 7.51% 10.73% 13.99% 10.90%      
Russell 3000® -3.48% 6.53% 10.03% 13.72% 10.66%      
Value Fund - Investor (WVALX) -3.50% 4.37% 6.53% 11.21% 10.10% 5/9/1986* 1.09% 1.23%
Value Fund - Institutional (WVAIX) -3.41% 4.58% 6.77% 11.36% 10.14% 7/31/2014 0.89% 1.08%
S&P 500® -3.08% 7.51% 10.73% 13.99% 10.90%      
Russell 1000® -2.81% 7.48% 10.47% 13.97% 10.25%      
ALLOCATION YTD 1 YR 5 YR 10 YR Since Fund Inception* Inception Date Net Expense Gross Expense
Balanced Fund - Investor (WBALX) -0.84% 3.57% 5.62% 7.26% 5.59% 10/1/2003* 0.85% 1.30%
Balanced Fund - Institutional (WBAIX) -0.74% 3.70% 5.64% 7.27% 5.60% 3/29/2019 0.70% 0.97%
Morningstar Moderately Conservative Target Risk 0.78% 5.74% 5.58% 6.43% 6.01%      
FIXED INCOME YTD 1 YR 5 YR 10 YR Since Fund Inception* Inception Date Net Expense Gross Expense
Core Plus Income Fund - Investor (WCPNX) 5.18% 7.41% 4.49% N/A 4.21% 7/31/2014* 0.50% 1.42%
Core Plus Income Fund - Institutional (WCPBX) 5.26% 7.50% 4.69% N/A 4.40% 7/31/2014* 0.40% 0.96%
Bloomberg Barclays U.S. Aggregate Bond 6.14% 8.74% 4.30% N/A 3.99%      
Nebraska Tax-Free Income Fund (WNTFX) 2.23% 3.21% 1.71% 1.93% 4.47% 10/1/1985* 0.45% 0.89%
Bloomberg Barclays 5-Year Municipal Bond 2.18% 3.80% 2.76% 2.91% N/A      
Short Duration Income Fund - Investor (WSHNX) 1.51% 2.73% 2.08% 2.05% 4.91% 8/1/2011 0.55% 0.92%
Short Duration Income Fund - Institutional (WEFIX) 1.57% 2.89% 2.29% 2.24% 4.97% 12/23/1988* 0.48% 0.63%
Bloomberg Barclays 1-3 Year U.S. Aggregate 2.68% 4.00% 2.07% 1.62% N/A      
Ultra Short Government Fund (SAFEX) 0.95% 1.94% 1.20% 0.61% 2.35% 8/1/1991* 0.20% 0.61%
ICE BofAML US 6-Month Treasury Bill 0.93% 2.11% 1.43% 0.82% 2.90%      

*Denotes the Funds inception date and the date from which Since Inception Performance is calculated. 

Data quoted is past performance and current performance may be lower or higher. Past performance is no guarantee of future results. Investment return and principal value of an investment will fluctuate, and shares, when redeemed, may be worth more or less than their original cost. All investments involve risks, including possible loss of principal. Please visit for the most recent month-end performance.

In Tour de France cycling terms, this spring was a “stage” that favored the sprinters. Investors enjoyed flat and downhill terrain, with a tailwind to boot. The more risk one took, the better. Our approach tends to excel in the mountain climbs, the grueling uphill stages that reward endurance over speed. Think of investing as a pursuit with a virtually unlimited number of quarterly stages, each with varied terrain. Our aim cannot be to win each stage, which is neither prudent nor possible. Rather, our goal is to deliver exceptional results for our investors over the full, long race.

For detailed information on moves we made in our portfolios last quarter, we urge shareholders to read the Portfolio Managers' fund commentaries and Tom and Nolan's Fixed Income Insights.

Market Commentary

The financial press is prone to exaggeration, but when it comes to the impact of the current pandemic, much of the hyperbole is warranted. Between the two of us, we have been managing money for a collective 75 years or so. Throughout that time, we have seen a lot, but today's combination of challenges is different. 

The country was not prepared for a healthcare crisis, and the policy response has been uneven, at best. The shutdown was considered necessary for controlling the virus but has been devastating for the economy. Research on treatments and vaccines has proceeded at a record pace, but fully solving the COVID-19 issue is probably years in the future. Fiscal and monetary measures have been massive, but their sustainability and long-term impacts are unknown. Changing attitudes about “togetherness” raise questions about the futures of the travel, hospitality and entertainment industries. Our nation's “crash course” in working and schooling from home will probably have lasting impacts on office real estate, distance education and childcare. The rest of the world is wrestling with the same issues, and there is great uncertainty as to supply chain viability and international trade.

A chart of the S&P 500 might lead one to believe that the world is back to normal. There are reasons to hope that the lows in economic activity are behind us. Better treatment options and vaccines are coming. Resistance to wearing masks seems to be waning. Testing and tracing should allow us to identify and isolate the infected while the vast majority go back to “normal” life. Our disagreement with the most optimistic case for stocks is in the timing

A recent resurgence in new COVID cases is a reminder that the recovery is more likely to proceed in fits and starts. Given investors' fixation on developments in the pandemic, we would expect periodic bouts of nervous selling. This is not a terrible thing — it is normal. But the first half “V-shaped” market recovery may turn out to have been the first leg of a “W” — or perhaps a series of W's.

Game Plan

"There are some new challenges to the investment puzzle today, but our philosophy and approach do not change."

There are some new challenges to the investment puzzle today, but our philosophy and approach do not change. We invest in stocks as if we were buying whole businesses. Although the economic future is murkier than usual, if we can buy shares in a business for less than an informed buyer would pay for the whole company, we are likely to earn reasonable long-term returns.

Financial strength is always important. We look for companies that generate more cash than they need to operate and that use debt financing sparingly. Cyclical businesses and those whose worlds are going to change dramatically post-pandemic are not automatically off our prospect list, but we do not want to base our investment decisions on hope or luck. As we've said before, if the investment thesis begins with “If this company survives the pandemic…” we are not interested.

For many of our portfolio holdings, stock prices are still materially down from their early 2020 highs. However, we were fortunate to have entered this crisis period with few of the obvious victims of the pandemic and recession. Jon Baker, CFA, our equity analyst who follows travel-related companies, was quick to sound the alarm when the virus first broke out in China, and we sold our two online travel companies. We also sold a supplier of airplane parts that would be expected to suffer from a sharp drop in air travel. Other stock sales in the first half of the year were mostly a matter of selling a stock we liked to buy another that we liked better.

We own some wonderful businesses whose stocks have been well-rewarded by investors. Some of these are mega-cap technology companies (Google, Microsoft, Amazon, Mastercard, Visa). Others are well-known providers of crucial products (Danaher, Fortive, Thermo Fisher Scientific, Texas Instruments, Analog Devices, IDEX). These stocks have recovered nicely and cannot be considered “cheap,” but we believe they can still generate reasonable returns over time.

We also own some other very good businesses that haven't been receiving as much attention from investors lately, but which we think will serve us well even if recovery takes much longer than people expect. Companies that include broadband providers (Comcast, Liberty Broadband, Liberty Global), financials (Schwab, JPMorgan, Markel), aggregate and cement suppliers for infrastructure (Martin Marietta, Vulcan, Summit), diagnostic medical tests (Laboratory Corp of America), and satellite radio entertainment (Liberty Sirius XM).

Finally, a good word for an old favorite — Berkshire Hathaway (BRK.B). We have owned BRK in our funds continuously since our opening day in 1983. It has been a major contributor over the years and is currently our largest stock position. BRK is down -21.2% so far this year, so it has been a drag on first-half results, but we think BRK was built for times like this and will prove its value (again) before the current crisis is over.

At BRK's virtual annual meeting on May 2, Warren Buffett told shareholders that he had not been a significant buyer of BRK or other stocks (yet) despite the major decline in the market. He explained that the range of possible outcomes of the pandemic was too wide for him to confidently make bold investment moves. He said that it would take time to understand how fundamental changes in human behavior would affect business values. His take was that recovery would not be immediate and that there would be ample opportunities for him to deploy his cash reserves (over $50 per equivalent Class B share as of 3/31) before the crisis was over.

In our estimation, BRK's business value is at least $230 per B share (28% higher than its current price) and we also think that it will grow at an average rate of at least 7% over the next several years. This is not “moonshot” material, but 7% growth and some narrowing of the discount between stock price and business value should look very good over the next few years.


"The world is a complicated place and there are lots of issues besides viruses to deal with, but from an investing perspective, we feel good about the future."

The volatility that has roiled the market in recent months has provided some good buying opportunities. Several of our new holdings are companies we have admired for years and finally had a chance to buy during the first-quarter decline. As always, we continue to evolve the on-deck list of businesses we would love to own (at the right price). The bar for portfolio entry is tougher than ever to clear, and competition for capital is increasingly robust. Credit again to our talented and experienced analyst team for their hard work on behalf of our investors.

We are optimistic that the country will solve its COVID crisis with a combination of science and sensible public policy, but it will probably take longer than investors expect. In the meantime, we are positioned to withstand further volatility and, hopefully, take advantage of opportunities that arise in periods of financial commotion. The world is a complicated place and there are lots of issues besides viruses to deal with, but from an investing perspective, we feel good about the future.

/sitefiles/live/documents/ValueMatters/2Q20_Value Matters.pdf
background Back to top